ProQR Therapeutics IPO Info
Company Name: ProQR Therapeutics
Stock Symbol: PRQR
Exchange: NASDAQ
Status: Priced
IPO Date: 9/18/2014
IPO Price:
13.00 (
66.69%)
Underwriters
Leerink Partners, Deutsche Bank Securities
Amount of Offering: N/A
Number of Shares Offered: 7.5 Mil
Shares Outstanding After Offering: N/A
Valuation: N/A
Company Description
ProQR Therapeutics is an innovative biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis, or CF. Utilizing our unique, proprietary RNA repair technologies, we believe we will be able to treat genetic disorders in which a single protein is defective due to certain types of genetic mutation. We design our therapeutic candidates to specifically target and repair the defective messenger RNA, or mRNA, that is a product of a mutated gene in order to restore the expression and function of normal, or wild-type, protein. Our technologies employ single-stranded RNA-based oligonucleotides, which act as guide sequences to repair the targeted abnormal mRNA. The repaired mRNA then acts as a template to generate wild-type protein to address the underlying cause of the genetic disorder. We believe that this is a unique approach that offers advantages compared with small molecule, gene therapy and other therapeutic strategies.
News Headlines
